-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Only for medical professionals to read and refer to clinical information, 1s reach proton pump inhibitor (PPI) is among the top 10 most commonly used drugs in the world, and is usually recommended for gastric acid-related diseases, such as gastroesophageal reflux disease, digestion Ulcer disease and non-ulcer dyspepsia, etc.
[1]
.
Recent studies have shown that PPI can affect the intestinal microbial community by changing the original gastrointestinal environment [2-3]
.
Moreover, more and more studies support the causal role of changes in the gut microbiota in the pathogenesis of metabolic diseases, such as type 2 diabetes (T2DM) [4-5]
.
Recently, Loosen SH and others published a paper in Gut, a top journal in the field of gastroenterology and liver disease, evaluating the correlation between the routine use of PPI and the risk of T2DM [6], let’s take a look at today’s Quick news! Want to track the subject areas you care about in real time? Want to see more previous issues of "Top Journal Essentials"? Hurry up to the "Clinical Assistant in the Medical Field" service account to have a look! Step 1: Follow the official account of "Clinical Assistant in Medical Field" Step 2: Find "Subscription Settings" in the lower menu bar to subscribe to the subject (subscribe to the daily push of the subject, read the new top issue every day) Step 3: Find it in the lower menu bar "Top Journal Essentials" to view the contents of previous issues (multiple keyword selection, key research not to be missed), read the cutting-edge literature every day, so let's use such a useful tool! References: [1] Targownik LE, Metge C, Roos L, et al.
The prevalence of and the clinical and demographic characteristics associated with high-intensity proton pump inhibitor use.
Am J Gastroenterol 2007;102:942–50.
[2 ] Jackson MA, Goodrich JK, Maxan ME, et al.
Proton pump inhibitors alter the composition of the gut microbiota.
Gut 2016;65:749–56.
[3] Naito Y, Kashiwagi K, Takagi T, et al.
Intestinal dysbiosis secondary to proton-pump inhibitor use.
Digestion 2018;97:195–204.
[4] Sanna S, van Zuydam NR, Mahajan A, et al.
Causal relationships among the gut microbiome,
.
Relevant parties are requested to check separately when adopting or using this as a basis for decision-making
.
[1]
.
Recent studies have shown that PPI can affect the intestinal microbial community by changing the original gastrointestinal environment [2-3]
.
Moreover, more and more studies support the causal role of changes in the gut microbiota in the pathogenesis of metabolic diseases, such as type 2 diabetes (T2DM) [4-5]
.
Recently, Loosen SH and others published a paper in Gut, a top journal in the field of gastroenterology and liver disease, evaluating the correlation between the routine use of PPI and the risk of T2DM [6], let’s take a look at today’s Quick news! Want to track the subject areas you care about in real time? Want to see more previous issues of "Top Journal Essentials"? Hurry up to the "Clinical Assistant in the Medical Field" service account to have a look! Step 1: Follow the official account of "Clinical Assistant in Medical Field" Step 2: Find "Subscription Settings" in the lower menu bar to subscribe to the subject (subscribe to the daily push of the subject, read the new top issue every day) Step 3: Find it in the lower menu bar "Top Journal Essentials" to view the contents of previous issues (multiple keyword selection, key research not to be missed), read the cutting-edge literature every day, so let's use such a useful tool! References: [1] Targownik LE, Metge C, Roos L, et al.
The prevalence of and the clinical and demographic characteristics associated with high-intensity proton pump inhibitor use.
Am J Gastroenterol 2007;102:942–50.
[2 ] Jackson MA, Goodrich JK, Maxan ME, et al.
Proton pump inhibitors alter the composition of the gut microbiota.
Gut 2016;65:749–56.
[3] Naito Y, Kashiwagi K, Takagi T, et al.
Intestinal dysbiosis secondary to proton-pump inhibitor use.
Digestion 2018;97:195–204.
[4] Sanna S, van Zuydam NR, Mahajan A, et al.
Causal relationships among the gut microbiome,
.
Relevant parties are requested to check separately when adopting or using this as a basis for decision-making
.
